FENEBRUTINIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H44N8O4
Molecular Weight	664.7965
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1CN(CCN1C2=CC=C(NC3=CC(=CN(C)C3=O)C4=C(CO)C(=NC=C4)N5CCN6C(=CC7=C6CC(C)(C)C7)C5=O)N=C2)C8COC8

InChI

InChIKey=WNEODWDFDXWOLU-QHCPKHFHSA-N

InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C37H44N8O4
Molecular Weight	664.7965
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29457982 | https://pubchem.ncbi.nlm.nih.gov/compound/gdc-0853 | https://www.ncbi.nlm.nih.gov/pubmed/29484638

G-0853 (also GDC-0853, or Fenebrutinib) is a potent, selective, orally administered, and noncovalent Bruton's tyrosine kinase (Btk) inhibitor currently in clinical development. Upon administration, G-0853 inhibits the activity of Btk and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and Btk-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK is overexpressed in B-cell malignancies, and plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival. G-0853 suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis. G-0853 demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein kinase BTK 24 Target ID: Q06187 Gene ID: 695.0 Gene Symbol: BTK Target Organism: Homo sapiens (Human) Sources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C116844	Inhibitor 8504

C_max

Value	Dose	Analyte	Population
0.0009 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.0022 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.0095 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.0354 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.068 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.153 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.633 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.7 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.883 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
0.0064 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.0144 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.0704 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.226 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.459 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.803 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.08 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.53 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.41 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
6.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.68 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29484638/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	FENEBRUTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:05:01 GMT 2025` Edited by `admin` on `Mon Mar 31 22:05:01 GMT 2025`
Record UNII	E9L2885WUL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

G-02599853

Preferred Name

English

FENEBRUTINIB

Official Name

English

fenebrutinib [INN]

Common Name

English

RG-7845

Code

English

RO7010939

Code

English

RG7845

Code

English

GDC-0853

Code

English

G02599853

Code

English

RO-7010939

Code

English

2H-CYCLOPENTA(4,5)PYRROLO(1,2-A)PYRAZIN-1(6H)-ONE, 2-(1,6-DIHYDRO-3'-(HYDROXYMETHYL)-1-METHYL-5-((5-((2S)-2-METHYL-4-(3-OXETANYL)-1-PIPERAZINYL)-2-PYRIDINYL)AMINO)-6-OXO(3,4'-BIPYRIDIN)-2'-YL)-3,4,7,8-TETRAHYDRO-7,7-DIMETHYL-

Systematic Name

English

FENEBRUTINIB [USAN]

Common Name

English

(S)-2-(3'-(HYDROXYMETHYL)-1-METHYL-5-((5-(2-METHYL- 4-(OXETAN-3-YL)PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-6-OXO-1,6-DIHYDRO-(3,4'-BIPYRIDIN)-2'-YL)-7,7-DIMETHYL-2,3,4,6,7,8-HEXAHYDRO-1H-CYCLOPENTA (4,5)PYRROLO(1,2-A)PYRAZIN-1-ONE

Systematic Name

English

Fenebrutinib [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C129825